Eye-focused Iveric Bio reports positive PhIII readout as shares surge, FDA filing planned
A biotech has claimed a second Phase III win, and that company is taking its win all the way to the bank — and ultimately the FDA.
New Jersey biotech Iveric Bio put out word of its positive results Tuesday, saying that the company’s drug candidate had met the primary endpoint of the mean rate of growth (slope) in geographic atrophy over 12 months. The study enrolled 448 patients with GA, the most advanced stage of dry AMD, also known as age-related macular degeneration.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.